[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549190":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":30,"locations":39,"responsibleParty":120,"collaborators":34,"id":122,"slug":123,"hasResults":124,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":34,"eligibilityCriteria":128,"healthyVolunteers":129,"sex":130,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":34,"studyType":136,"phases":137,"briefSummary":139,"conditions":140,"keywords":144,"overallStatus":42,"whyStopped":34,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Emapalumab, then Standard IST","EXPERIMENTAL","Participants will first receive Emapalumab for 6 weeks. After treatment with emapalumab, participants will receive standard IST with drugs called equine anti-thymocyte globulin (hATG) and cyclosporin (CsA) in addition to a lower dose of emapalumab",[13],"Biological: Emapalumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Emapalumab, then HCT","Participants will first receive Emapalumab for 6 weeks. After treatment with emapalumab, participants will have a standard hematopoietic stem cell transplant (HCT).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","Emapalumab","Emapalumab is an interferon gamma (IFNγ) blocking antibody",[15,9],[25],"Gamifant",[27],{"name":28,"affiliation":5,"role":29},"Andromachi Scaradavou, MD","PRINCIPAL_INVESTIGATOR",[31,36],{"name":28,"role":32,"phone":33,"phoneExt":34,"email":35},"CONTACT","1-833-MSK-KIDS",null,"ScaradaA@mskcc.org",{"name":37,"role":32,"phone":33,"phoneExt":34,"email":38},"Jaap Jan Boelens, MD, PhD","boelensj@mskcc.org",[40,55,70,84,98,112],{"facility":41,"status":42,"city":43,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)","RECRUITING","New York","10065","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-74.00597,40.71427,{"lat":51,"lon":50},[54],{"name":28,"role":32,"phone":33,"phoneExt":34,"email":34},{"facility":56,"status":42,"city":57,"state":58,"zip":59,"country":45,"countryCode":46,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Cincinnati Children's Hospital Medical Center (Data collection only)","Cincinnati","Ohio","45229",{"type":48,"coordinates":61},[62,63],-84.51439,39.12711,{"lat":63,"lon":62},[66],{"name":67,"role":32,"phone":68,"phoneExt":34,"email":69},"Anthony Sabulski, MD","513-636-3200","anthony.sabulski@cchmc.org",{"facility":71,"status":42,"city":72,"state":73,"zip":74,"country":45,"countryCode":46,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Children's Hospital of Philadelphia (Data Collection AND Specimen Analysis)","Philadelphia","Pennsylvania","19104",{"type":48,"coordinates":76},[77,78],-75.16362,39.95238,{"lat":78,"lon":77},[81],{"name":82,"role":32,"phone":83,"phoneExt":34,"email":34},"Tim Olson, MD, PhD","800-879-2467",{"facility":85,"status":42,"city":86,"state":87,"zip":88,"country":45,"countryCode":46,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Virginia Commonwealth University (Data Collection Only )","Richmond","Virginia","23219",{"type":48,"coordinates":90},[91,92],-77.46026,37.55376,{"lat":92,"lon":91},[95],{"name":96,"role":32,"phone":97,"phoneExt":34,"email":34},"Joe Laver, MD, MHA","804-828-9213",{"facility":99,"status":42,"city":100,"state":101,"zip":102,"country":45,"countryCode":46,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Children's Hospital of Wisconsin (Data Collection Only)","Milwaukee","Wisconsin","53226",{"type":48,"coordinates":104},[105,106],-87.90647,43.0389,{"lat":106,"lon":105},[109],{"name":110,"role":32,"phone":111,"phoneExt":34,"email":34},"Larisa Broglie, MD","414-266-2420",{"facility":113,"status":114,"city":100,"state":101,"zip":102,"country":45,"countryCode":46,"cosmosGeoPoint":115,"geoPoint":117,"contacts":118},"Medical College of Wisconsin (Data Collection AND Data Analysis)","NOT_YET_RECRUITING",{"type":48,"coordinates":116},[105,106],{"lat":106,"lon":105},[119],{"name":110,"role":32,"phone":111,"phoneExt":34,"email":34},{"type":121,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100549190","phase-2-a-study-of-emapalumab-for-pediatric-aplastic-anemia-100549190",false,"NCT06430788","A Study of Emapalumab for Pediatric Aplastic Anemia","Phase 2a\u002F2b Study Emapalumab: A Window of Opportunity in Pediatric Aplastic Anemia","Inclusion Criteria:\n\n* Patients undergoing workup for suspected newly diagnosed sAA:\n\n  * Patients with severe cytopenias and a hypocellular marrow concerning for sAA\n  * Patients that meet the definition for suspected sAA (Camitta Criteria) as follows:\n\nMarrow Cellularity: \\\u003C25%, or 25-50% with \\\u003C30% residual hematopoietic cells Peripheral cytopenias (at least 2 of 3) Absolute neutrophil count (ANC): \\\u003C500 x 10\\^9\u002FL Platelets: \\\u003C20 x 10\\^9\u002FL Absolute Reticulocyte Count: \\\u003C60 x 10\\^9\u002FL\n\n* Patients that do not have evidence of leukemia or MDS\n* Patients \\\u003C 25 years of age at time of diagnosis\n* Able to tolerate emapalumab and IST (with standard institutional organ function criteria)\n\nExclusion Criteria:\n\n* Uncontrolled infection at presentation.\n* Patients who have undergone previous treatment for sAA.\n* Patients with known inherited bone marrow failure\n* Patient who has completed a full workup for sAA including having results back from telomere testing, DEB and genetics (when applicable), as well as having an appropriate willing and available donor and would otherwise be admitted for HSCT within 2 weeks of enrolling on the trial\n* Patients with leukemia or MDS\n* Patient or parent or guardian unable to give informed consent or unable to comply with the treatment protocol including research tests.",true,"ALL","0 Years","25 Years",{"count":134,"type":135},35,"ESTIMATED","INTERVENTIONAL",[138],"PHASE2","The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options.\n\nFunding Source- FDA OOPD",[141,142,143],"Aplastic Anemia","Cytopenia","Hypocellular Marrow",[145,146,147,148,21,5,149],"pediatric aplastic anemia","aplastic anemia","cytopenia","hypocellular marrow","23-278","2025-12-11",{"date":152,"type":153},"2025-12-17","ACTUAL",{"date":155,"type":153},"2024-05-21",{"date":157,"type":135},"2029-05-21",{"name":5,"class":6},6]